You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康芝藥業(300086.SZ):蘇拉明鈉藥物對Omicron變異株有明顯抗病毒作用
格隆匯 03-31 18:33

格隆匯3月31日丨康芝藥業(300086.SZ)公佈,公司近日收到廣東省公共衞生研究院針對該次“橫向科研項目研究合作協議”研發項目的《蘇拉明鈉對SARS-CoV-2病毒變異株的敏感性研究報吿》。

項目研究新冠病毒感染細胞後,實驗藥物蘇拉明鈉與對照藥物瑞德西韋對病毒複製的抑制作用。兩者均可以在體外細胞(Vero-E6)中抑制新冠病毒Omicron變異株的複製。蘇拉明鈉藥物在無明顯細胞毒性的藥物濃度下表現出對SARS-CoV-2病毒Omicron變異株明顯抗病毒作用,實驗中蘇拉明鈉藥物對Omicron變異株的抑制指數為239.9。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account